Hashimoto’s Thyroiditis Drug Market is Poised to Garner High Revenues Owing to Increasing Disease Prevalence
Hashimoto’s Thyroiditis Drug Market |
Hashimoto's thyroiditis, also known as chronic
lymphocytic thyroiditis, is the most common cause of hypothyroidism. It is an
autoimmune disease where the immune system attacks the thyroid gland, leading
to inflammation and damage over time. Symptoms include fatigue, weight gain,
feeling cold, constipation, depression, muscle and joint pain. Drugs used for
treatment include levothyroxine for lifelong hormone replacement and
corticosteroids in certain cases to reduce inflammation.
The global
Hashimoto’s thyroiditis drug market is estimated to be valued at US$ 2.18
billion in 2024 and is expected to exhibit a CAGR of 5.8% over the forecast
period from 2024 to 2031.
Key Takeaways
Key players operating in the Hashimoto’s thyroiditis drug are AbbVie Inc.,
Merck & Co., Allergan., Amneal Pharmaceuticals., Lannett Company, Mylan
Pharmaceuticals, Pfizer, Akorn Pharmaceuticals, Acella Pharmaceuticals, Jerome
Stevens Pharmaceuticals and Other Prominent Players. These companies are
focusing on developing novel drugs and expanding their production facilities to
cater to the growing demand.
The key opportunities in the Hashimoto's
Thyroiditis Drugs Market Demand include increasing research for developing
targeted therapies, expanding into developing regions with high disease burden
but low treatment rate and launching affordable generic drugs.
The major players are actively pursuing global expansion strategies through
collaborations with regional pharmaceutical companies, acquisitions and
licensing agreements. For instance, AbbVie partnered with 3SBio to
commercialize levothyroxine sodium in China in 2020.
Market Drivers
Growing disease prevalence globally due to rising environmental risk factors
and genetic predisposition is a major market driver. Estimates suggest the
incidence has doubled in the last few decades. Another key driver is increasing
awareness and diagnostic rates leading to early identification and treatment
seeking behavior.
Market Restraints
High cost of branded drugs, especially newly launched targeted therapies pose a
major challenge. Generic drugs have lower compliance due to less convenient
dosing. Lack of awareness in developing nations also restricts the market
growth. Additionally, social stigma around thyroid disorders limits treatment
seeking to some extent.
Comments
Post a Comment